Cite it or cut it

---

Every number in ShotLock traces to a published source — or it doesn't ship. Here's exactly how the estimates work and where they come from.

Medication level estimates

We model each dose with standard one-compartment pharmacokinetics (a Bateman absorption/elimination curve), using absorption and half-life parameters from FDA labels and published literature — roughly 7 days of half-life for semaglutide, around 5 for tirzepatide. Your displayed level is the sum of every logged dose's remaining contribution. It's an estimate of shape and rhythm, not a lab value.

Trial benchmarks

Progress comparisons use published trial curves: STEP 1 (semaglutide 2.4 mg, ~15% average body-weight reduction at 68 weeks) and SURMOUNT-1 (tirzepatide, up to ~21% at 72 weeks). Mid-trial points are estimated from published figures; endpoint values are exact. Trial participants also received lifestyle support — your context differs, and the benchmark is shown as context, never a target.

Side-effect context

When ShotLock says '~20% of trial participants reported nausea', that incidence comes from the cited trial's safety tables. Your in-app comparisons are computed from your own logs on your device.

The Research Library

Every claim in the app links to its source in the built-in Research Library — trial papers, FDA labels, peer-reviewed reviews. Our internal rule is enforced by automated tests: content without a registered citation fails the build.

ShotLock is not a medical device and provides no medical advice. Estimates and benchmarks are informational. Always follow your healthcare provider's plan.